查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1870858

厌食症市场按治疗方法、疗法、最终用户和年龄组别划分 - 全球预测 2025-2032 年

Anorexia Nervosa Market by Treatment Type, Therapy Type, End User, Age Group - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 185 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，神经性厌食症市场将成长至 2.986 亿美元，复合年增长率为 13.70%。

主要市场统计数据
基准年 2024 1.0687亿美元
预计年份：2025年 1.2183亿美元
预测年份：2032年 2.986亿美元
复合年增长率 (%) 13.70%

针对神经性厌食症的综合框架强调了整合的临床要务、符合发展阶段的应对措施以及不断发展的服务管道，旨在改善患者的治疗效果。

神经性厌食症是行为健康领域最顽固、最复杂的挑战之一，它不仅涉及严重的营养障碍，还伴随着根深蒂固的心理模式，需要协调一致的临床应对。近年来，临床实践和政策的进步提高了人们对该疾病长期致残性的认识，并强调了在急性期、过渡时期和社区护理的各个阶段建立整合管道的必要性。过去十年，临床医生和医疗系统日益重视早期发现、家庭参与式照护模式以及衔接医疗稳定性、营养復健和针对性心理治疗的多学科干预措施。

技术应用、早期疗育策略以及支付方主导的整合正在重新定义临床环境中的护理路径和治疗强度。

随着临床实务、技术和政策的交会融合，厌食症的治疗模式正在发生显着变化，治疗路径和病患体验也随之重塑。远端医疗的扩展已从疫情期间的权宜之计转变为一种可持续的方法，它与面对面咨询相辅相成，使患者能够跨越地域限制获得持续的医疗服务，并改善服务不足地区的就医途径。同时，数位化评估工具和远端监测平台正在帮助临床医生追踪患者就诊间生理参数和症状的变化，从而实现更及时的干预，并在治疗的关键早期阶段降低风险。

不断变化的关税政策对供应链、实验室物流和筹资策略的影响，进而影响厌食症专科护理的连续性和成本。

关税政策和不断变化的跨境贸易动态对供应链、药品进口以及医疗服务中使用的专用医疗设备的成本结构都产生了下游影响。对于依赖进口营养品、医疗监测设备和特殊配方的医疗机构而言，关税波动正迫使其调整筹资策略和库存管理，从而重新评估采购结构和库存缓衝，以确保医疗服务的连续性。医疗系统和独立医疗机构正在透过扩大供应商选择范围、尽可能增加在地采购以及协商更灵活的合约条款来应对关税波动带来的风险。

透过整合治疗环境、治疗方法、提供者类型和发展阶段，落实差异化照护路径并取得更佳疗效。

按治疗类型细分护理连续体，揭示了不同的资源和临床强度特征，因此需要采取差异化的营运应对措施。日间护理计画、住院护理和住宿护理各自需要特定的人员编制模式、临床管治和医疗监测通讯协定。患者在这些护理等级之间的过渡受益于标准化的交接流程和共用的疗效评估指标，从而最大限度地减少临床挫折。同时，不同的治疗方法也影响临床重点和训练需求。营养咨询为体重恢復和饮食支持奠定了基础；药物治疗（包括非典型抗精神病药物和选择性血清素再回收抑制剂的选择性使用）针对合併症状；心理治疗（透过认知行为疗法、家庭疗法和人际关係疗法）则着重解决疾病的认知和关係因素。

从区域观点探讨影响饮食障碍治疗服务取得、服务设计和创新的临床基础设施、文化动态和政策框架。

区域动态影响着从临床文化到法规结构和报销机制的方方面面，导致不同地区的服务可及性和照护模式存在差异。在美洲，强大的研究基础、集中化的卓越临床中心以及不断发展的支付模式正在推动整合式医疗管道的创新，但农村和都市区仍然存在医疗资源获取方面的差距。该地区的医疗服务提供者正越来越多地采用远端医疗和协作式护理模式，将专业知识扩展到社区，而支付方则在探索以以金额为准的合约模式，以奖励持续康復和减少医疗併发症。

评估透过整合系统、专科诊所、远端医疗平台和临床开发人员提供跨专业护理的组织格局

参与神经性厌食症治疗的组织生态系统包括综合医疗系统、专业行为健康诊所、远端医疗平台以及提供辅助工具用于监测和症状管理的製药和医疗设备开发商。医疗系统和医院是医疗稳定和复杂合併症管理的中心，通常与专科诊所合作，以确保心理社会照护的连续性。专科诊所通常汇集多学科护理团队的专业知识，包括营养师、心理学家、精神科医生和护士，以开发可在不同服务领域复製的治疗方案。

医疗保健经营团队的策略重点：扩大临床照护、整合远端医疗、加强采购和建立以结果为导向的临床管治。

致力于加强神经性厌食症服务的领导者应优先考虑扩大临床服务能力，同时确保服务品质和连续性。首先，应投资于人力资源开发，重点为包括医生、营养师、心理健康临床医生和护理协调员在内的多学科团队提供基于能力的培训，并在各级引入标准化的交接流程，以降低不同层级护理之间的过渡风险。其次，应策略性地整合远端医疗，以扩大专科护理的覆盖范围并实现分级诊疗模式。将高强度的线下治疗项目与线上追踪和看护者指导相结合，以维持治疗效果并降低再入院率。

一种透明、多方面的方法，结合文献综述、专家访谈和营运数据，以临床证据为基础得出可操作的见解。

本研究综合运用了系统性文献回顾、专家访谈和多学科证据评估，以确保提供全面且具有临床基础的观点。同行评审的临床研究、实践指南和共识声明为治疗和干预建议提供了临床框架，而对临床医生、计画主管和支付方的定性访谈则提供了运营背景，并深入分析了就医障碍和报销动态。来自服务提供者和技术供应商的数据则为医疗服务创新提供了见解，尤其关注远端医疗和远端监测的作用。

整合临床和营运重点，透过综合性、发展敏感度和适应性发展阶段。

神经性厌食症的治疗正处于一个转捩点。儘管临床进展、服务模式创新和政策转变为改善治疗效果创造了机会，但也需要整个治疗链中各机构采取策略性应对措施。需求显而易见：优先考虑早期介入和家庭参与式干预，整合医疗和社会心理护理，并利用远端医疗和数位监测来提高服务的可及性和连续性。同时，营运韧性，尤其是在采购和供应链规划方面，对于防止可能损害復原的服务中断至关重要。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 人工智慧驱动的数位筛检工具问世，用于早期检测神经性厌食症
  • 扩大远端保健平台，提供远距饮食障碍治疗和支持
  • 将基因和肠道菌丛分析整合到个人化营养补充品中
  • 虚拟实境暴露疗法在改善患者扭曲的身体意象方面正得到越来越广泛的应用。
  • 增加对含有认知行为疗法模组的行动心理健康应用程式的投资，以治疗厌食症
  • 透过加强保险公司和专科诊所之间的合作，改善患者获得治疗的机会。
  • 利用社交媒体建立由同侪主导的线上復健社区，促进病人参与

第六章美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 厌食症市场（依治疗方法）

  • 日间治疗计划
  • 住院治疗
  • 住院治疗

9. 厌食症治疗市场

  • 营养咨询
  • 药物治疗
    • 非典型抗精神病药物
    • 选择性血清素再回收抑制剂（SSRIs）
  • 心理治疗
    • 认知行为疗法
    • 家庭治疗
    • 人际关係疗法

第十章 以最终用户分類的神经性厌食症市场

  • 医院
  • 专科诊所
  • 远端医疗提供者

第十一章 依年龄组别分類的神经性厌食症市场

  • 青春期
  • 成人
  • 儿童

第十二章 各地区的神经性厌食症市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 神经性厌食症市场（依群体划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 各国神经性厌食症市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Acadia Healthcare Company, Inc.
    • Universal Health Services, Inc.
    • Rogers Behavioral Health
    • Eating Recovery Center, LLC
    • Monte Nido & Affiliates, LLC
    • Walden Behavioral Care, Inc.
    • The Renfrew Center, Inc.
    • Priory Group Ltd
Product Code: MRR-1A1A064C0422

The Anorexia Nervosa Market is projected to grow by USD 298.60 million at a CAGR of 13.70% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 106.87 million
Estimated Year [2025] USD 121.83 million
Forecast Year [2032] USD 298.60 million
CAGR (%) 13.70%

A comprehensive framing of anorexia nervosa that highlights integrated clinical imperatives, developmental tailoring, and the evolving delivery pathways for improved patient outcomes

Anorexia nervosa presents one of the most persistent and complex challenges in behavioral health, combining severe nutritional compromise with entrenched psychological patterns that demand coordinated clinical responses. Recent clinical practice and policy developments have heightened awareness of the condition's long-term morbidity and the need for integrated pathways across acute, intermediate, and community settings. Over the past decade clinicians and health systems have increasingly prioritized earlier identification, family-inclusive models of care, and multidisciplinary interventions that bridge medical stabilization, nutritional rehabilitation, and targeted psychotherapy.

This executive summary synthesizes clinically relevant evidence and service-delivery trends to support decision-makers in healthcare delivery, policy, and life sciences. It focuses on the modalities that shape care access and quality, including treatment settings, therapy approaches, provider types, and age-specific adaptations. While clinical nuance varies by patient presentation, common themes emerge: the imperative of tailoring interventions to developmental stage, the critical role of coordinated medical oversight during weight restoration, and the centrality of psychosocial therapies to sustain recovery. In addition, evolving care delivery mechanisms and payer interactions are influencing how services are organized and reimbursed, with implications for clinical outcomes and operational sustainability.

Taken together, these considerations underscore the need for strategic investments in workforce training, care integration, and evidence-based program design to meet rising clinical complexity and evolving patient expectations.

How technological adoption, earlier intervention strategies, and payer-driven integration are redefining care pathways and treatment intensity across clinical settings

The landscape of anorexia nervosa care has shifted markedly as clinical practice, technology, and policy intersect to reshape treatment trajectories and patient experience. Telehealth expansion has moved from a pandemic-era stopgap to a durable modality that augments in-person care, enabling continuity for patients across distances and improving access for those in underserved regions. Concurrently, digital assessment tools and remote monitoring platforms support clinicians in tracking physiological parameters and symptom trajectories between visits, which in turn informs more timely interventions and reduces risk during the critical early phases of treatment.

At the same time, clinical paradigms have evolved to favor earlier engagement and family-inclusive strategies, driven by evidence supporting improved outcomes with developmentally attuned interventions. Psychotherapeutic modalities such as cognitive behavioral therapy and family-based approaches have seen refinements in protocols and wider adoption across settings, while nutritional counseling has been integrated more closely with medical oversight to accelerate stabilization without compromising psychological work. Pharmacotherapy continues to play a secondary yet important role, primarily for co-occurring psychiatric symptoms and selective indications; the use of atypical antipsychotics and selective serotonin reuptake inhibitors remains targeted and adjunctive rather than primary.

These transformative shifts have been reinforced by payer and policy adjustments that emphasize stepped-care pathways, quality metrics tied to clinical outcomes, and incentives for integrated behavioral health models. As a result, providers and system leaders are redesigning care pathways to balance intensity, accessibility, and quality across day treatment programs, inpatient hospitalization, and residential treatment modalities.

Impacts of evolving tariff policies on supply chains, clinical trials logistics, and procurement strategies that influence continuity and cost of specialized anorexia nervosa care

Changes in tariff policy and cross-border trade dynamics have downstream effects on supply chains, pharmaceutical imports, and the cost structure of specialized medical equipment used in care delivery. For providers reliant on imported nutritional products, medical monitoring devices, or specialty formulations, shifts in tariffs alter procurement strategies and inventory management, prompting organizations to reassess sourcing arrangements and inventory buffers to maintain continuity of care. Health systems and independent providers are responding by broadening supplier panels, increasing local procurement where feasible, and negotiating more flexible contracting terms to mitigate exposure to tariff volatility.

Pharmaceutical development and clinical trials can also be affected indirectly through changes in the cost base for importing investigational supplies and equipment. Clinical program managers and sponsors are integrating tariff considerations into trial budgeting and logistics planning to avoid disruptions to dosing regimens or monitoring schedules. In tandem, international collaborations for research and training may require recalibration of resource flows and event planning when cross-border expenses shift.

Importantly, shifts in trade policy compel payer and provider procurement teams to adopt scenario planning that anticipates periods of price instability, with an emphasis on maintaining clinical quality and uninterrupted access to essential supplies. By embedding tariff sensitivity into supply-chain governance and contracting, organizations can preserve treatment continuity and protect vulnerable patients from gaps in care that could adversely affect clinical recovery trajectories.

Segmentation-driven insights that align treatment setting, therapeutic modality, provider type, and developmental stage to operationalize differentiated care pathways for better outcomes

Disaggregating the care continuum by treatment type reveals distinct resource and clinical intensity profiles that require differentiated operational responses. Day Treatment Program, Inpatient Hospitalization, and Residential Treatment each demand specific staffing models, clinical governance, and medical monitoring protocols; transitioning patients between these levels of care benefits from standardized handoffs and shared outcome metrics to minimize clinical regression. By contrast, therapy modality distinctions shape the clinical focus and training needs: Nutritional Counseling serves as the backbone of weight restoration and meal support, Pharmacotherapy-used selectively and inclusive of Atypical Antipsychotics and Selective Serotonin Reuptake Inhibitors-targets comorbid symptoms, and Psychotherapy-implemented through Cognitive Behavioral Therapy, Family Based Therapy, and Interpersonal Therapy-addresses the cognitive and relational drivers of illness.

End-user segmentation highlights where investment and innovation can have immediate operational impact. Hospitals deliver integrated medical stabilization and psychiatric liaison services; Specialized Clinics concentrate on multidisciplinary eating-disorder expertise and programmatic continuity; and Telehealth Providers extend reach and continuity through virtual platforms that support outpatient follow-up and caregiver coaching. Each end-user type faces unique challenges in workforce development, reimbursement navigation, and quality assurance.

Age-based considerations are equally critical: adolescents often require family-centered interventions and coordination with schools, adults may present with longer illness duration and comorbidities necessitating coordinated medical and psychiatric management, and children call for developmentally calibrated approaches that balance parental involvement with age-appropriate engagement. By weaving together treatment type, therapy approach, provider setting, and age group considerations, stakeholders can design care pathways that align clinical intensity with patient needs and system capacity.

A regional perspective on how clinical infrastructure, cultural dynamics, and policy frameworks shape access, service design, and innovation in eating-disorder care

Regional dynamics shape everything from clinical culture to regulatory frameworks and reimbursement practices, driving variation in service availability and care models across geographies. In the Americas, robust research infrastructure, concentrated centers of clinical excellence, and evolving payer models have driven innovations in integrated care pathways, while persistent access gaps remain in rural and underserved urban communities. Providers in this region increasingly adopt telehealth and collaborative care arrangements to extend specialty expertise into community settings, and payers are exploring value-based arrangements that reward sustained recovery and reduced medical complications.

Across Europe, Middle East & Africa, heterogeneity in healthcare systems produces a wide range of access and delivery models. Some European countries have well-established national pathways and funding mechanisms for specialized eating-disorder services, whereas other jurisdictions contend with limited specialist capacity and stigma-related barriers to care. In parts of the Middle East and Africa, community outreach and task-shared models are gaining traction to address shortages in specialist clinicians, and partnerships between public and private providers are emerging to expand access.

In the Asia-Pacific region, growing clinical recognition and investment in mental health services are expanding the landscape of care, yet cultural factors and resource constraints shape help-seeking behaviors and service design. Telehealth and digital education initiatives are accelerating uptake, while localized adaptations of evidence-based therapies aim to improve acceptability and adherence. Across all regions, cross-border collaboration in research, training, and guideline development offers opportunities to disseminate best practices and reduce fragmentation in service delivery.

Assessing the organizational landscape where integrated systems, specialized clinics, telehealth platforms, and clinical developers converge to deliver multidisciplinary care

The ecosystem of organizations active in anorexia nervosa care spans integrated health systems, specialized behavioral health clinics, telehealth platforms, and pharmaceutical and device developers that supply adjunctive tools for monitoring and symptom management. Health systems and hospitals serve as hubs for medical stabilization and complex comorbidity management, often partnering with specialized clinics to ensure continuity of psychosocial care. Specialized clinics concentrate expertise in multidisciplinary care teams, including dietitians, psychologists, psychiatrists, and nurse practitioners, and they often develop programmatic pathways that can be replicated across service lines.

Telehealth providers have scaled models for virtual therapy, caregiver coaching, and stepped-care follow-up, reducing geographic barriers to specialist consultation and enabling more frequent touchpoints that support adherence. Meanwhile, pharmaceutical companies and clinical-stage developers continue to explore pharmacologic approaches for symptom management and comorbidities, recognizing that medication remains adjunctive to core psychosocial and nutritional interventions. Device and digital health vendors are introducing remote monitoring tools and adherence supports that facilitate earlier clinical intervention and more granular outcome tracking.

From an operational perspective, collaboration across these organization types is critical: integrated pathways between hospitals, specialized clinics, and telehealth platforms reduce fragmentation; partnerships with technology vendors enhance monitoring capabilities; and strategic alignment with clinical researchers accelerates the translation of evidence into practice. Stakeholders that cultivate these collaborative linkages position themselves to deliver more coordinated, patient-centered care.

Actionable strategic priorities for healthcare executives to scale capacity, integrate telehealth, fortify procurement, and embed outcome-driven clinical governance

Leaders seeking to strengthen anorexia nervosa services should prioritize actions that scale clinical capacity while safeguarding quality and continuity. First, invest in workforce development that emphasizes competency-based training for multidisciplinary teams, including physicians, dietitians, mental health clinicians, and care coordinators, and embed standardized handoff protocols across levels of care to reduce risk during transitions. Second, integrate telehealth strategically to extend specialty reach and enable stepped-care models, combining high-intensity in-person programs with virtual follow-up and caregiver coaching to sustain gains and reduce readmissions.

Third, develop robust supply-chain and procurement strategies that anticipate cost volatility and ensure uninterrupted access to essential nutritional products and monitoring equipment. Fourth, strengthen measurement systems that track clinical outcomes, functional recovery, and patient experience, and use these metrics to inform continuous improvement and payer negotiations. Fifth, foster cross-sector partnerships with academic centers and clinical researchers to participate in trials and translational studies that expand treatment options and refine best practices.

Finally, prioritize equity and cultural competence in program design by adapting therapies and outreach approaches to meet the needs of diverse populations and reduce stigma-related barriers. By advancing these priorities in parallel-workforce, telehealth integration, procurement resilience, measurement, research partnerships, and equity-organizations can build sustainable programs that deliver measurable clinical benefit and improve long-term recovery trajectories.

A transparent multi-source methodology combining literature synthesis, expert interviews, and operational data to derive clinically grounded and implementable insights

This research synthesis combines systematic literature review, expert interviews, and cross-disciplinary evidence appraisal to ensure a comprehensive and clinically grounded perspective. Peer-reviewed clinical trials, practice guidelines, and consensus statements provided the clinical scaffold for therapy and treatment recommendations, while qualitative interviews with clinicians, program directors, and payers furnished operational context and insights into barriers to access and reimbursement dynamics. Data from service providers and technology vendors informed considerations of care delivery innovation, particularly the role of telehealth and remote monitoring.

Analytic rigor was maintained through triangulation of sources and iterative validation with subject-matter experts, including clinicians experienced in adolescent and adult eating-disorder care, dietitians, and clinical operations leaders. Where primary evidence was limited-such as in novel digital interventions or emerging procurement impacts-interpretation emphasized pragmatic implications rather than definitive claims, and uncertainty was explicitly noted. Ethical and methodological standards guided the inclusion of studies, with attention to study quality, sample characteristics, and generalizability to routine clinical settings.

The synthesis deliberately avoided speculative financial estimations and instead prioritized clinically meaningful patterns, operational levers, and regional considerations to support strategic decision-making by providers, payers, and commercial partners.

Synthesis of clinical and operational priorities that reinforce integrated, developmentally informed, and resilient approaches to delivering high-quality anorexia nervosa care

Anorexia nervosa care is at an inflection point where clinical advances, delivery-model innovation, and policy shifts create opportunities to improve outcomes but also demand strategic responses from organizations across the care continuum. The imperative is clear: prioritize early and family-inclusive interventions, integrate medical and psychosocial care, and leverage telehealth and digital monitoring to augment access and continuity. Concurrently, operational resilience-particularly in procurement and supply-chain planning-remains essential to prevent service interruptions that can undermine recovery.

Stakeholders that invest in workforce competencies, standardized care pathways, and cross-sector partnerships will be better positioned to translate evidence into routine practice and to meet diverse patient needs across developmental stages. Regional differences remain salient, and the most effective programs will adapt global best practices to local cultural, regulatory, and resource realities. Ultimately, progress will depend on aligning clinical excellence with sustainable operations and payer engagement so that high-quality, accessible care becomes the norm rather than the exception.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Emergence of AI-enabled digital screening tools for early anorexia nervosa detection
  • 5.2. Expansion of telehealth platforms offering remote eating disorder therapy and support
  • 5.3. Integration of personalized nutritional supplements based on genetic and gut microbiome analysis
  • 5.4. Rising adoption of virtual reality exposure therapy to address body image distortions in patients
  • 5.5. Increased investment in mobile mental health apps with cognitive behavioral therapy modules for anorexia
  • 5.6. Growth of collaboration between insurance providers and specialist clinics to improve treatment access
  • 5.7. Development of peer-led online recovery communities leveraging social media for patient engagement

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Anorexia Nervosa Market, by Treatment Type

  • 8.1. Day Treatment Program
  • 8.2. Inpatient Hospitalization
  • 8.3. Residential Treatment

9. Anorexia Nervosa Market, by Therapy Type

  • 9.1. Nutritional Counseling
  • 9.2. Pharmacotherapy
    • 9.2.1. Atypical Antipsychotics
    • 9.2.2. Selective Serotonin Reuptake Inhibitors
  • 9.3. Psychotherapy
    • 9.3.1. Cognitive Behavioral Therapy
    • 9.3.2. Family Based Therapy
    • 9.3.3. Interpersonal Therapy

10. Anorexia Nervosa Market, by End User

  • 10.1. Hospitals
  • 10.2. Specialized Clinics
  • 10.3. Telehealth Providers

11. Anorexia Nervosa Market, by Age Group

  • 11.1. Adolescents
  • 11.2. Adults
  • 11.3. Children

12. Anorexia Nervosa Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Anorexia Nervosa Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Anorexia Nervosa Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2024
  • 15.2. FPNV Positioning Matrix, 2024
  • 15.3. Competitive Analysis
    • 15.3.1. Acadia Healthcare Company, Inc.
    • 15.3.2. Universal Health Services, Inc.
    • 15.3.3. Rogers Behavioral Health
    • 15.3.4. Eating Recovery Center, LLC
    • 15.3.5. Monte Nido & Affiliates, LLC
    • 15.3.6. Walden Behavioral Care, Inc.
    • 15.3.7. The Renfrew Center, Inc.
    • 15.3.8. Priory Group Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. ANOREXIA NERVOSA MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 28. ANOREXIA NERVOSA MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANOREXIA NERVOSA MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANOREXIA NERVOSA MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY DAY TREATMENT PROGRAM, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INPATIENT HOSPITALIZATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY RESIDENTIAL TREATMENT, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY NUTRITIONAL COUNSELING, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ATYPICAL ANTIPSYCHOTICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SELECTIVE SEROTONIN REUPTAKE INHIBITORS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COGNITIVE BEHAVIORAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY FAMILY BASED THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY INTERPERSONAL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY HOSPITALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY SPECIALIZED CLINICS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY TELEHEALTH PROVIDERS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADOLESCENTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY ADULTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY CHILDREN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 121. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 122. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 123. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 124. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 125. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 126. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 127. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 128. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 129. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 130. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 131. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 132. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 133. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 134. AMERICAS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 135. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 136. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 137. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 138. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 139. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 140. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 141. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 142. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 143. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 144. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 145. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 146. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 147. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 148. NORTH AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 149. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 150. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 151. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 152. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 153. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 154. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 155. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 156. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 157. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 158. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 159. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 160. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 161. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 162. LATIN AMERICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 168. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 169. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 170. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 171. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 172. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 173. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 174. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 175. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 176. EUROPE, MIDDLE EAST & AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 177. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 178. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 179. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 180. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 181. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 182. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 183. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 184. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 185. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 186. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 187. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 188. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 189. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. EUROPE ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 194. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 195. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 196. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 197. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 198. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 199. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 200. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 201. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 202. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 203. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. MIDDLE EAST ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 208. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 209. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 210. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 211. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 212. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 213. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 214. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 215. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 216. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 217. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 218. AFRICA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 219. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 220. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 221. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 222. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 223. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 224. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 225. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 226. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 227. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 228. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 229. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 230. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 231. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. ASIA-PACIFIC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 235. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 236. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 237. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 238. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 239. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 240. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 241. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 242. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 243. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 244. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 245. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 246. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 247. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. ASEAN ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GCC ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 252. GCC ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 253. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 254. GCC ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 255. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 256. GCC ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 257. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 258. GCC ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 259. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 260. GCC ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 261. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 262. GCC ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 275. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 276. EUROPEAN UNION ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 277. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 278. BRICS ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 279. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 280. BRICS ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 281. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 282. BRICS ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 283. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 284. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 285. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 286. BRICS ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 287. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 288. BRICS ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 289. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 290. BRICS ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 291. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 292. G7 ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 293. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 294. G7 ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 295. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 296. G7 ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 297. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 298. G7 ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 299. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 300. G7 ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 301. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 302. G7 ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 303. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 304. G7 ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 305. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 306. NATO ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 307. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 308. NATO ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 309. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 310. NATO ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 311. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 312. NATO ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 313. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 314. NATO ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 315. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 316. NATO ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 317. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 318. NATO ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 319. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 320. GLOBAL ANOREXIA NERVOSA MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 321. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 322. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 323. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 324. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 325. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 326. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 327. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 328. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 329. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 330. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 331. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 332. UNITED STATES ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)
  • TABLE 333. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2018-2024 (USD MILLION)
  • TABLE 334. CANADA ANOREXIA NERVOSA MARKET SIZE, BY TREATMENT TYPE, 2025-2032 (USD MILLION)
  • TABLE 335. CANADA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 336. CANADA ANOREXIA NERVOSA MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 337. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 338. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PHARMACOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 339. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2018-2024 (USD MILLION)
  • TABLE 340. CANADA ANOREXIA NERVOSA MARKET SIZE, BY PSYCHOTHERAPY, 2025-2032 (USD MILLION)
  • TABLE 341. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
  • TABLE 342. CANADA ANOREXIA NERVOSA MARKET SIZE, BY END USER, 2025-2032 (USD MILLION)
  • TABLE 343. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2018-2024 (USD MILLION)
  • TABLE 344. CANADA ANOREXIA NERVOSA MARKET SIZE, BY AGE GROUP, 2025-2032 (USD MILLION)

TAB